Viltolarsen
An article about the drug Viltolarsen
Viltolarsen | |
---|---|
![]() | |
INN | |
Drug class | |
Routes of administration | |
Pregnancy category | |
Bioavailability | |
Metabolism | |
Elimination half-life | |
Excretion | |
Legal status | |
CAS Number | |
PubChem | |
DrugBank | |
ChemSpider | |
KEGG |
Viltolarsen is a pharmaceutical drug used in the treatment of Duchenne muscular dystrophy (DMD), a severe type of muscular dystrophy characterized by rapid progression of muscle degeneration. Viltolarsen is specifically designed to target mutations in the dystrophin gene that are amenable to exon 53 skipping.
Mechanism of Action[edit | edit source]
Viltolarsen is an antisense oligonucleotide that works by binding to exon 53 of the dystrophin pre-mRNA. This binding causes the exon to be skipped during mRNA splicing, resulting in the production of a truncated but functional dystrophin protein. This mechanism is intended to partially restore the function of the dystrophin protein in patients with specific genetic mutations.
Clinical Use[edit | edit source]
Viltolarsen is indicated for the treatment of patients with Duchenne muscular dystrophy who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. It is administered via intravenous infusion and is typically given on a weekly basis.
Side Effects[edit | edit source]
Common side effects of Viltolarsen include injection site reactions, upper respiratory tract infections, and fever. Patients receiving Viltolarsen should be monitored for potential adverse reactions, and the drug should be used with caution in patients with renal impairment.
Development and Approval[edit | edit source]
Viltolarsen was developed by Nippon Shinyaku and NS Pharma. It received accelerated approval from the United States Food and Drug Administration (FDA) in 2020 based on its ability to increase dystrophin production in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD, Dr.T